Headline News Archive
Click on title to read the full article.
The manly side of a woman's disease
September 22, 2020
By Andrea Markowitz, Chicago Tribune
Low awareness that men can get breast cancer may result in delayed treatment and poorer outcomes.
Val Lucier is a male breast cancer survivor. He considers himself lucky that he detected his cancer at Stage 3B — an advanced stage in which cancer has spread into lymph nodes, and at which a patient's chance of surviving the cancer five years from the time of diagnosis is 41 percent, according to the American Cancer Society.
Novel medicinal mushroom blend suppresses growth and invasiveness of human breast cancer cells
September 17, 2020
By INTERNATIONAL JOURNAL OF ONCOLOGY 37: 1529-1536, 2010
Abstract. Mushrooms are an integral part of Traditional Chinese Medicine (TCM), and have been used for millennia to prevent or treat a variety of diseases. Currently mushrooms or their extracts are used globally in the form of dietary supplements. In the present study we have evaluated the anticancer effects of the dietary supplement
Genentech Provides Update on Avastin for Advanced Breast Cancer
September 17, 2020
By Genentech Press Release
South San Francisco, Calif. — September 17, 2020 — Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment. In accordance with FDA guidelines, the agency has extended the review period for the sBLAs by an additional 90 days. The company now anticipates FDA action on the sBLAs by December 17, 2020
FDA Approves High-Dose Fulvestrant for Refractory Metastatic Breast Cancer
September 17, 2020
By Yael Waknine, Medscape Infectious Diseases
The US Food and Drug Administration (FDA) has approved a 500-mg dose of fulvestrant intramuscular injection (Faslodex; AstraZeneca) for the treatment of hormone receptor–positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Genentech Breast Cancer Drug Denied Accelerated Approval
September 8, 2020
By FDA News
Genentech has been denied accelerated approval for its investigational breast cancer treatment trastuzumab-DM1 (T-DM1), a move likely to push the drug’s potential market entry back at least two years. The FDA issued a refuse-to-file letter for the BLA for T-DM1, a combination of Genentech’s Herceptin (trastuzumab) and ImmunoGen’s cancer-killing agent DM1, because all available treatment options for metastatic breast cancer were not exhausted
Headline News Archive
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- October 2007
- September 2007